Illegal Ginkgo biloba extract event in fermentation industry or spread to the whole industry

After the illegal Ginkgo biloba extract incident started in the middle of May attracted great attention of the public, the incident has not stopped at present Some analysts in the industry did not want to be named pointed out to NetEase Finance and economics, although the food and drug administration asked relevant enterprises to ensure that the recalled drugs should be fully recalled before June 3 "But at present, the impact of this event can not be stopped in the short term, or it will continue to affect and affect the whole industry." The State Food and Drug Administration previously reported that in order to reduce costs, two enterprises, Guilin Xingda Pharmaceutical Co., Ltd and WAN Bangde (Hunan) Natural Medicine Co., Ltd., illegally changed the production process of Ginkgo biloba leaf extraction from dilute ethanol extraction to 3% hydrochloric acid extraction, and the ginkgo leaf extract products produced basically lost clinical efficacy Li Guoqing, director of the Department of pharmaceutical and chemical supervision of the State Food and drug administration, said that among the 24 pharmaceutical companies that have purchased such products, it has been confirmed that some enterprises have used such Ginkgo biloba extract products for drug production According to the report, Guilin Xingda Pharmaceutical Co., Ltd not only changed the production process of ginkgo leaf extraction from dilute ethanol extraction to 3% hydrochloric acid extraction, but also purchased ginkgo leaf extract produced by hydrochloric acid process from unqualified enterprises, which was used to produce ginkgo leaf, and sold the purchased extract to other pharmaceutical manufacturers, forged the purchase account and production of raw materials Inspection records It is reported that many of the pharmaceutical manufacturers involved are listed companies, including Yunnan Baiyao Group traditional Chinese Medicine Resources Co., Ltd., Qianyuan pharmaceutical and Fangsheng pharmaceutical and LVYE Pharmaceutical Co., Ltd listed in Hong Kong According to the food and drug administration, the above-mentioned drug manufacturing enterprises also have the behavior of selling the problem products to other drug producing enterprises For example, Yunnan Baiyao announced that its subsidiary traditional Chinese medicine resource company had purchased the illegal Ginkgo biloba extract and sold 6.9 tons of products to Anning Branch of Yunnan Xitao green Pharmaceutical Co., Ltd Yunnan Xitao green Pharmaceutical Co., Ltd is a subsidiary of Kangenbei, a well-known domestic pharmaceutical enterprise "In response to the demand of downstream customer Yunnan xitaoanning branch to carry out foreign business, traditional Chinese medicine resource company purchased five batches of 6.9 tons of Ginkgo biloba extract from Guilin Xingda with Ginkgo biloba extract production qualification and sold them to Yunnan xitaoanning branch Up to now, all the goods have been sent to Yunnan xitaoanning branch." Under the "self inspection" order issued by the State Food and drug administration, new companies are constantly involved On May 31, the State Food and Drug Administration issued the notice on further improving the special treatment of Ginkgo biloba drugs on its official website, which requires relevant enterprises to "ensure that all recalled drugs are in place before June 3" As of June 1, nine listed companies have announced various measures for Ginkgo biloba extract products, including Qianyuan pharmaceutical, Fangsheng pharmaceutical, Yunnan Baiyao, Haiwang biological, Kangenbei, Hansen pharmaceutical, Yibai pharmaceutical, Xinbang pharmaceutical, etc In this regard, a source in the industry who did not want to be named pointed out to NetEase Finance and economics that as the production of Ginkgo biloba extract is highly concentrated in the current Chinese pharmaceutical production enterprises, with the development of the event, more and more enterprises may be affected "The impact of this event cannot be stopped in the short term, or it will continue to affect and affect the whole industry." It is reported that Ginkgo biloba extract has been developed in Germany since 1965 and has been widely used in the world, mainly in neurology, cardiology, geriatrics, traditional Chinese medicine and health care By 2013, the annual sales of Ginkgo biloba preparations (including injections) on the global market reached 7 billion US dollars At present, China has 117 approvals for Ginkgo biloba oral preparations In addition, China has become the world's largest producer of Ginkgo biloba extract According to Bosch data, the global production of Ginkgo biloba extract is mainly concentrated in China, Germany and France In 2013, the annual output of the above three countries accounted for 78.3% of the total global output Among them, the output of Ginkgo biloba extract in China is 348.6 tons, accounting for 48.52% of the global output in the same period; the output of Germany is 107.3 tons, accounting for 14.93%; the output of France is 106.8 tons, accounting for 14.86% According to the data base of CFDA, as of January 2015, there were 113 domestic manufacturers and sellers of Ginkgo biloba extract, including 13 injection and 100 oral preparations According to incomplete statistics, there are more than 300 manufacturers in the current ginkgo processing industry chain, mainly producing Ginkgo biloba extract and downstream products, including drugs, health products, cosmetics, food and beverage series products.